Constantin
@constantindyd.bsky.social
🧠 Neuroscientist | 💊Drug hunter | 🤝 People leader | 📈 Aspiring Entrepreneur | Fighting Neurodegenerative Diseases | 🖼️ Arts & 📚 Book Lover
Gala dinner of the synuclein meeting at King’s college, Cambridge, UK. What a setting! ❤️
April 10, 2025 at 10:36 PM
Gala dinner of the synuclein meeting at King’s college, Cambridge, UK. What a setting! ❤️
Virginia Lee, PhD in stage at the 2025 #synuclein meeting, Cambridge, UK. She doesn’t need an introduction. 80 years old and still going strong as a key opinion leader in neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. #parkinson #synuclein #drugdiscovery #neuroscience
April 10, 2025 at 3:36 PM
Virginia Lee, PhD in stage at the 2025 #synuclein meeting, Cambridge, UK. She doesn’t need an introduction. 80 years old and still going strong as a key opinion leader in neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. #parkinson #synuclein #drugdiscovery #neuroscience
Great presentations, posters and discussions at the 2025 synuclein meeting in Cambridge, UK! #synuclein #parkinsonsdisease #drugdiscovery
April 10, 2025 at 12:01 PM
Great presentations, posters and discussions at the 2025 synuclein meeting in Cambridge, UK! #synuclein #parkinsonsdisease #drugdiscovery
A letter from the Editors of the international scientific journal Nature to President-Elect Mr. Trump. Worth a read !
Dear Donald Trump: A letter from Nature on how to make science thrive
The US federal government can harness science to secure the health, prosperity and safety of Americans and the world.
www.nature.com
January 17, 2025 at 1:47 PM
A letter from the Editors of the international scientific journal Nature to President-Elect Mr. Trump. Worth a read !
🧠 The Race to Treat Alzheimer’s: Are We on the Right Path?
Pharma focused on amyloid- and tau-targeting therapies, with recent approvals marking a turning point. Yet, these therapies face questions about efficacy, costs, etc.
But are amyloid and tau the endgame, or should we broaden our horizons?
Pharma focused on amyloid- and tau-targeting therapies, with recent approvals marking a turning point. Yet, these therapies face questions about efficacy, costs, etc.
But are amyloid and tau the endgame, or should we broaden our horizons?
January 17, 2025 at 10:54 AM
🧠 The Race to Treat Alzheimer’s: Are We on the Right Path?
Pharma focused on amyloid- and tau-targeting therapies, with recent approvals marking a turning point. Yet, these therapies face questions about efficacy, costs, etc.
But are amyloid and tau the endgame, or should we broaden our horizons?
Pharma focused on amyloid- and tau-targeting therapies, with recent approvals marking a turning point. Yet, these therapies face questions about efficacy, costs, etc.
But are amyloid and tau the endgame, or should we broaden our horizons?
🌟 Hello Bluesky! 🌟
🧠 Who I Am:
I’m a neuroscientist with a passion for understanding the brain, a drug hunter dedicated to discovering therapies, a leader who gets energized when building high performing teams.
#Neuroscience #Biotech #Pharma #DrugDiscovery
January 16, 2025 at 10:15 AM
🌟 Hello Bluesky! 🌟
🧠 Who I Am:
I’m a neuroscientist with a passion for understanding the brain, a drug hunter dedicated to discovering therapies, a leader who gets energized when building high performing teams.
#Neuroscience #Biotech #Pharma #DrugDiscovery